Tislelizumab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Tislelizumab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Introduction

Tislelizumab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb, is a therapeutic antibody that has been developed as a biosimilar to the original Tislelizumab antibody. This biosimilar is designed to target the programmed cell death protein 1 (PD-1), which is a key immune checkpoint receptor that plays a crucial role in regulating the immune response. In this article, we will explore the structure, activity, and applications of Tislelizumab Biosimilar in research.

Structure of Tislelizumab Biosimilar

Tislelizumab Biosimilar is a monoclonal antibody that is composed of two identical heavy chains and two identical light chains. The heavy chains are approximately 150 kDa in size, while the light chains are approximately 25 kDa in size. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the top and a crystallizable fragment (Fc) at the bottom. The Fc region is responsible for the effector functions of the antibody, while the Fab region is responsible for binding to its target, PD-1.

Activity of Tislelizumab Biosimilar

Tislelizumab Biosimilar works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This interaction is crucial for the downregulation of T cell activity, which is necessary to prevent an excessive immune response. However, in cancer, this interaction can be exploited by tumor cells to evade the immune system. Tislelizumab Biosimilar binds to PD-1 with high affinity, preventing its interaction with PD-L1 and PD-L2. This allows T cells to remain active and target cancer cells, leading to their destruction.

Applications of Tislelizumab Biosimilar

1.

Cancer Immunotherapy

The primary application of Tislelizumab Biosimilar is in cancer immunotherapy. The overexpression of PD-L1 on tumor cells is a common mechanism of immune evasion in various cancers. By blocking the PD-1/PD-L1 interaction, Tislelizumab Biosimilar can enhance the anti-tumor immune response and potentially lead to tumor regression. This has been demonstrated in preclinical studies and clinical trials, where Tislelizumab Biosimilar has shown promising results in various types of cancer, including lung cancer, melanoma, and bladder cancer.

2. Autoimmune Diseases Aside from its use in cancer, Tislelizumab Biosimilar has also shown potential in the treatment of autoimmune diseases. PD-1 is involved in maintaining self-tolerance and preventing autoimmunity. In diseases such as rheumatoid arthritis and multiple sclerosis, there is evidence of PD-1 dysfunction. By targeting PD-1, Tislelizumab Biosimilar may be able to restore immune balance and potentially improve disease outcomes.

3. Research Tool Tislelizumab Biosimilar is also a valuable research tool for studying the PD-1/PD-L1 pathway. Its high specificity and affinity for PD-1 make it a useful tool for investigating the role of this pathway in various diseases and for screening potential therapeutic agents. Additionally, Tislelizumab Biosimilar can be used to assess the expression of PD-1 in different tissues and cell types, which can provide valuable insights into the regulation of the immune response.

Conclusion

In summary, Tislelizumab Biosimilar is a promising therapeutic antibody that targets PD-1 and has shown potential in cancer immunotherapy and the treatment of autoimmune diseases. Its unique structure and high specificity make it a valuable research tool for studying the PD-1/PD-L1 pathway. As research and clinical trials continue, Tislelizumab Biosimilar has the potential to improve outcomes for patients with various diseases and contribute to a better understanding of the immune system.

Tislelizumab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Tislelizumab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1479) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450